153 related articles for article (PubMed ID: 38090374)
1. The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010-2019).
Cao Y; Ye LM; Fan Z; Yang W; Chen LY; Mei Y; He DY; Mo WJ
Cancer Innov; 2023 Feb; 2(1):79-90. PubMed ID: 38090374
[TBL] [Abstract][Full Text] [Related]
2. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
Chen H; Zhou Y; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
[TBL] [Abstract][Full Text] [Related]
3. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
4. Differences in Investigator-Initiated Trials between Japan and Other Countries: Analyses of Clinical Trials Sponsored by Academia and Government in the ClinicalTrials.gov Registry and in the Three Japanese Registries.
Ito T
PLoS One; 2016; 11(2):e0148455. PubMed ID: 26848574
[TBL] [Abstract][Full Text] [Related]
5. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
6. Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT).
Blümle A; Wollmann K; Bischoff K; Kapp P; Lohner S; Nury E; Nitschke K; Zähringer J; Rücker G; Schumacher M
BMC Med Res Methodol; 2021 Aug; 21(1):182. PubMed ID: 34465296
[TBL] [Abstract][Full Text] [Related]
7. Panoramic quality assessment tool for investigator initiated trials.
Lv W; Hu T; Jiang J; Qu T; Shen E; Duan J; Miao X; Zhang W; Qian B
Front Public Health; 2022; 10():988574. PubMed ID: 36176521
[TBL] [Abstract][Full Text] [Related]
8. Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.
Jia W; Yu H; Song L; Wang J; Niu S; Zang G; Liang M; Liu J; Na R
Front Med (Lausanne); 2023; 10():1239351. PubMed ID: 38034540
[TBL] [Abstract][Full Text] [Related]
9. Impact of investigator initiated trials and industry sponsored trials on medical practice (IMPACT): rationale and study design.
Nury E; Bischoff K; Wollmann K; Nitschke K; Lohner S; Schumacher M; Rücker G; Blümle A
BMC Med Res Methodol; 2020 Oct; 20(1):246. PubMed ID: 33008297
[TBL] [Abstract][Full Text] [Related]
10. The Development of Investigator-Initiated Clinical Trials in Surgical Oncology.
McDonald HG; Cassim EB; Harper MM; Burke EE; Marcinkowski EF; Cavnar MJ; Pandalai PK; Kim J
Surg Oncol Clin N Am; 2023 Jan; 32(1):13-25. PubMed ID: 36410913
[TBL] [Abstract][Full Text] [Related]
11. Investigational medicinal products, related costs and hospital pharmacy services for investigator-initiated trials: A mixed-methods study.
Taji Heravi A; Henn A; Deuster S; McLennan S; Gloy V; Mitter VR; Briel M;
PLoS One; 2022; 17(3):e0264427. PubMed ID: 35245312
[TBL] [Abstract][Full Text] [Related]
12. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer.
Tsai S; Evans DB
J Surg Oncol; 2022 Jan; 125(1):69-74. PubMed ID: 34897709
[TBL] [Abstract][Full Text] [Related]
15. Current Status and Challenges of Cancer Clinical Trials in Korea.
Shim BY; Park SH; Lee S; Kim JS; Lee KE; Kang YK; Ahn MJ
Cancer Res Treat; 2016 Jan; 48(1):20-7. PubMed ID: 25761486
[TBL] [Abstract][Full Text] [Related]
16. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011-2020).
Chen C; Lou N; Zheng X; Wang S; Chen H; Han X
Front Med (Lausanne); 2021; 8():777698. PubMed ID: 34977078
[No Abstract] [Full Text] [Related]
17. Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology.
Xu C; Zhang S; Zhu GL; Yang KB; Zhang Y; Mao YP; Tang LL; Liu Q; Huang Y; Ma J
Int Rev Immunol; 2023; 42(2):91-100. PubMed ID: 35712868
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficiency of clinical trials by standardizing processes for Investigator Initiated Trials.
Mudaranthakam DP; Phadnis MA; Krebill R; Clark L; Wick JA; Thompson J; Keighley J; Gajewski BJ; Koestler DC; Mayo MS
Contemp Clin Trials Commun; 2020 Jun; 18():100579. PubMed ID: 32510004
[TBL] [Abstract][Full Text] [Related]
19. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
20. Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories.
Fan R; Zheng Y; Zhou R; Beeraka NM; Sukocheva OA; Zhao R; Li S; Zhao X; Liu C; He S; Mahesh PA; Gurupadayya BM; Nikolenko VN; Zhao D; Liu J
Front Med (Lausanne); 2023; 10():1203346. PubMed ID: 37901406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
